{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:53:37Z","timestamp":1768697617613,"version":"3.49.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12,15]]},"DOI":"10.2146\/ajhp110134","type":"journal-article","created":{"date-parts":[[2011,12,2]],"date-time":"2011-12-02T04:52:32Z","timestamp":1322801552000},"page":"2335-2340","source":"Crossref","is-referenced-by-count":10,"title":["Dalfampridine: A new agent for symptomatic management of multiple sclerosis"],"prefix":"10.1093","volume":"68","author":[{"given":"Sarah","family":"McDonald","sequence":"first","affiliation":[{"name":"Martinsburg Veterans Affairs Medical Center (VAMC), Martinsburg, WV; at the time of writing she was Postgraduate Year 1 Pharmacy Practice Resident, Martinsburg VAMC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer N.","family":"Clements","sequence":"additional","affiliation":[{"name":"Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041106120659800_b1-0682335","unstructured":"National Multiple Sclerosis Society. Multiple sclerosis: just the facts. www.nationalmssociety.org\/about-multiple-sclerosis-what-we-know-about-ms\/what-is-ms\/index.aspx (accessed 2011 Jun 1)."},{"key":"key\n\t\t\t\t2019041106120659800_b2-0682335","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.mcna.2008.09.014","article-title":"Multiple sclerosis","volume":"93","author":"Courtney","year":"2009","journal-title":"Med Clin North Am"},{"key":"key\n\t\t\t\t2019041106120659800_b3-0682335","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/B978-0-7506-7525-3.50092-3","article-title":"Multiple sclerosis and other demyelinating disorders of the central nervous system","volume-title":"Neurology in clinical practice","author":"Lubin","year":"2008","edition":"5th ed"},{"key":"key\n\t\t\t\t2019041106120659800_b4-0682335","volume-title":"Ampyra (dalfampridine) package insert","year":"2010"},{"key":"key\n\t\t\t\t2019041106120659800_b5-0682335","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t2019041106120659800_b6-0682335","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.58.2.169","article-title":"Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines","volume":"58","author":"Goodin","year":"2002","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019041106120659800_b7-0682335","unstructured":"Miller A Cohen B Cohen J . Disease management consensus statement, 2007. www.nationalmssociety.org\/about-multiple-sclerosis\/what-we-know-about-ms\/treatments\/download.aspx?id=8 (accessed 2010 Mar 1)."},{"key":"key\n\t\t\t\t2019041106120659800_b8-0682335","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ncl.2011.01.008","article-title":"Symptomatic management in multiple sclerosis","volume":"29","author":"Samkoff","year":"2011","journal-title":"Neurol Clin"},{"key":"key\n\t\t\t\t2019041106120659800_b9-0682335","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/1352458506070658","article-title":"Gait and balance impairment in early multiple sclerosis in the absence of clinical disability","volume":"12","author":"Martin","year":"2006","journal-title":"Mult Scler"},{"key":"key\n\t\t\t\t2019041106120659800_b10-0682335","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/0091270009344857","article-title":"Single-dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment","volume":"50","author":"Smith","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041106120659800_b11-0682335","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.clinthera.2009.10.007","article-title":"Steady-state pharmacokinetics and tolerability of orally administrated fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study","volume":"31","author":"Vollmer","year":"2009","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019041106120659800_b12-0682335","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.clinthera.2009.10.008","article-title":"Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial","volume":"31","author":"Vollmer","year":"2009","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019041106120659800_b13-0682335","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1352458506069538","article-title":"Fampridine-SR in multiple sclerosis: a randomized double-blind, placebo-controlled, dose ranging study","volume":"13","author":"Goodman","year":"2007","journal-title":"Mult Scler"},{"key":"key\n\t\t\t\t2019041106120659800_b14-0682335","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.wnl.0000326213.89576.0e","article-title":"Dose comparison trial of sustained-release fampridine in multiple sclerosis","volume":"71","author":"Goodman","year":"2008","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019041106120659800_b15-0682335","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1212\/WNL.48.4.817","article-title":"Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis","volume":"48","author":"Schwid","year":"1997","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019041106120659800_b16-0682335","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019041106120659800_b17-0682335","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained-release oral fampridine in multiple sclerosis: a randomized, double-blind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041106120659800_b18-0682335","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.22240","article-title":"A phase 3 trial of extended release oral dalfampridine in multiple sclerosis","volume":"68","author":"Goodman","year":"2010","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t2019041106120659800_b19-0682335","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1212\/01.wnl.0000339380.23073.58","article-title":"4-Aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis","volume":"71","author":"Burton","year":"2008","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019041106120659800_b20-0682335","unstructured":"Acorda Therapeutics. Ampyra (dalfampridine) information. http:\/\/ampyra-hcp.com\/hcp\/all_about_ampyra (accessed 2011 Jul 18)."},{"key":"key\n\t\t\t\t2019041106120659800_b21-0682335","unstructured":"Acorda Therapeutics. Ampyra (dalfampridine) risk evaluation and mitigation strategy. www.ampyra.com\/local\/files\/rems.pdf (accessed 2011 Jul 18)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/68\/24\/2335\/28350577\/ajhp2335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T05:08:22Z","timestamp":1561007302000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/68\/24\/2335\/5129590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,15]]},"references-count":21,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2011,12,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp110134","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,12,15]]},"published":{"date-parts":[[2011,12,15]]}}}